

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 10, 2021
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 02, 2019
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Factor VII Deficiency.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 14, 2017
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Factor VII Deficiency.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 12, 2015
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Blood Coagulation Disorders.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 12, 2014
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Blood Coagulation Disorders.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 25, 2013
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Blood Coagulation Disorders.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 18, 2012
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Blood Coagulation Disorders.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 18, 2012
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Blood Coagulation Disorders.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 29, 2012
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
